Blood Cell Technologies
Early-stage R&D biopharmaceutical company focused on identification, validation and preclinical development of novel cellular drug targets, small-molecule inhibitors, and biomarkers with emphasis on hematology, metabolism, antioxidant biology and oncology. Active in target discovery, medicinal chemistry, structure-informed design, biomarker development and preclinical validation.
Industries
Nr. of Employees
small (1-50)
Products
BLVRB inhibitor development program
Preclinical development program for small-molecule inhibitors of biliverdin IXβ reductase (BLVRB) intended to enhance megakaryocyte and platelet production.
BLVRB Inhibitors
Small molecule biliverdin IXβ reductase (BLVRB) inhibitors developed to enhance megakaryocyte and platelet formation for the treatment of thrombocytopenia.
BLVRB inhibitor development program
Preclinical development program for small-molecule inhibitors of biliverdin IXβ reductase (BLVRB) intended to enhance megakaryocyte and platelet production.
BLVRB Inhibitors
Small molecule biliverdin IXβ reductase (BLVRB) inhibitors developed to enhance megakaryocyte and platelet formation for the treatment of thrombocytopenia.
Services
Discovery, design and optimization of small-molecule inhibitors targeting validated hematology-related enzymes; includes computational design, synthesis and preclinical testing.
Discovery, design and optimization of small-molecule inhibitors targeting validated hematology-related enzymes; includes computational design, synthesis and preclinical testing.
Expertise Areas
- Target identification and validation
- Small-molecule drug discovery and medicinal chemistry
- Structure-based drug design
- Biomarker discovery and assay development
Key Technologies
- Computational molecular modeling
- X-ray crystallography / structure-guided design
- De novo organic synthesis
- Small-molecule biochemical and cellular screening
News & Updates
Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo
Manuscript reporting in vivo preclinical results for a BLVRB inhibitor promoting megakaryocyte and platelet formation.
Manuscript linking BLVRB to breast cancer biology and proposing BLVRB as a therapeutic target.
International PCT patent publication related to BLVRB inhibitors.
Award for development of second generation BLVRB inhibitors for treating chemotherapy-induced thrombocytopenia.
SBIR Phase II award ($2.07M) for optimization of BLVRB redox inhibitors as reagents for enhancing platelet production.
Early SBIR Phase I awards supporting BLVRB inhibitor development and platelet RNA biomarker detection projects (2015, 2017, 2020).
Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo
Manuscript reporting in vivo preclinical results for a BLVRB inhibitor promoting megakaryocyte and platelet formation.
Manuscript linking BLVRB to breast cancer biology and proposing BLVRB as a therapeutic target.
International PCT patent publication related to BLVRB inhibitors.
Award for development of second generation BLVRB inhibitors for treating chemotherapy-induced thrombocytopenia.
SBIR Phase II award ($2.07M) for optimization of BLVRB redox inhibitors as reagents for enhancing platelet production.
Early SBIR Phase I awards supporting BLVRB inhibitor development and platelet RNA biomarker detection projects (2015, 2017, 2020).